3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Lymphoma
10
Breast Neoplasms
8
Neutropenia
7
Leukemia, Myeloid, Acute
7
Multiple Myeloma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Hematologic Neoplasms
4
Febrile Neutropenia
4
Leukemia, Monocytic, Acute
3
Leukemia, Biphenotypic, Acute
3
Hodgkin Disease
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Osteosarcoma
2
Myelodysplastic Syndromes
2
Leukemia, Myelomonocytic, Chronic
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Teratoma
1
Solid Tumors
1
Sarcoma, Myeloid
1
Sarcoma, Clear Cell
1
Rhabdoid Tumor
1
Retinoblastoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Interventions
pembrolizumab
162
Carboplatin
144
Paclitaxel
125
Cyclophosphamide
93
130-nm albumin-bound paclitaxel
66
Capecitabine
63
Gemcitabine
54
Doxorubicin
49
Albumin-Bound Paclitaxel
45
Taxes
42
atezolizumab
40
Cisplatin
38
Nivolumab
34
sacituzumab govitecan
32
olaparib
32
Epirubicin
32
Docetaxel
28
eribulin
27
Specimen Handling
26
Bevacizumab
26
durvalumab
25
camrelizumab
23
Drug Therapy
22
Biopsy
22
Magnetic Resonance Spectroscopy
21
toripalimab
18
Radiotherapy
17
spartalizumab
16
Everolimus
15
fludarabine
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Triple Negative Breast Neoplasms
×
pegylated granulocyte colony-stimulating factor
×
Clear all
NCT05076682
2025-12-03
Renaissance
Fudan University
Phase 2
Recruiting
80 enrolled